THE INVESTOR

▶주메뉴 바로가기

▶본문 바로가기

The Korea Herald

Bio & Medicine

April 01, 2019
Kolon Life Science suspends sales of Invossa

Kolon Life Science announced on April 1 that it has decided to suspend sales of its new osteoarthritis drug Invossa. According to the company, the decision was made after the its US unit Kolon TissueGene found going through the advanced and recently developed examination method STR that a compon...
March 27, 2019
[ANALYSIS] Market upbeat on Daewoong’s prospects for this year

South Korea’s bio sector is gaining both attention and traction, with many claiming their successful global expansion. While not all of them can deliver on their word, Daewoong Pharmaceutical is one of the few companies here that is expecting to benefit from its past investments. The company is ...
March 26, 2019
Celltrion CEO aims to sell Truxima in US this year

Celltrion ’s founder and Chairman Seo Jung-jin announced on March 26 that the company aims to begin selling its biosimilar Truxima in the US within the second half of this year. Seo -- who is in Tokyo on business -- made the announcement over the phone during Celltrion’s 28th shareholders meeti...
March 21, 2019
NPS to oppose Samsung Biologics’ proposals for shareholders meeting

National Pension Service has decided to oppose key proposals by Samsung Biologics ahead of the company’s scheduled shareholders meeting on March 22. The key proposals include approval of the financial statement and appointment of inside and outside executives. After having a meeting on March 20,...
March 21, 2019
SK Biopharmaceuticals’ narcolepsy drug to hit US market

SK Biopharmaceuticals, the new drug development unit of South Korea’s telecom-to-energy conglomerate SK Group, announced on March 21 that it has received marketing approval from the US Food and Drug Administration for its narcolepsy drug Sunosi based on solriamfetol, a compound it discovered. Sun...
March 20, 2019
SillaJen to secure additional funds worth W110b

South Korea’s biotherapeutics firm SillaJen announced on March 20 that it has decided to secure additional funds worth 110 billion won ($97.31 million) through issuing convertible bonds. The company said that the funds will mainly be used for developing its drug candidate Pexa-Vec, an oncolytic...
March 19, 2019
Korean pharma firms aiming higher with new drugs this year

Korean pharmaceutical companies have high hopes of leaping forward this year by boosting research and development to develop new drugs. According to a survey conducted by the Korea Pharmaceutical and Bio-Pharma Manufacturers Association, over 100 Korean pharma firms possess a total of 953 self-dev...
March 18, 2019
Donga Pharma’s diabetes drug to reach India

South Korean drug maker Donga Pharmaceutical said on March 18 that it will roll out its diabetes drug Suganon in India next month. India-based pharmaceutical firm Alkem Laboratories won exclusive rights to distribute and market the treatment medicine for type 2 diabetes. It will be officially a...
March 18, 2019
Drug makers decide on capital spending

Several South Korean pharmaceutical companies have decided to make new facility investments in a bid to hone their competitiveness, industry sources said on March 18. The decisions, made at annual shareholder meetings, are seen as reflecting their efforts to streamline and expand infrastructure...
March 15, 2019
Prosecutors raid Seoul bourse in Samsung BioLogics probe

Prosecutors raided South Korea’s main stock exchange on March 15 as part of a probe into alleged accounting fraud by Samsung BioLogics. Investigators from the Seoul Central District Prosecutors’ Office were sent to search the Korea Exchange in western Seoul. They also raided the offices o...
March 15, 2019
Naver to start health care biz with Daewoong

South Korean internet giant Naver said on March 15 that it has established a joint venture with Daewoong Pharmaceutical to provide medical data analysis services based on its artificial intelligence technology. Seoul National University Budang Hospital will also be working with the new JV as a...
March 14, 2019
Daewoong Pharma seeks to expand in Vietnam with Traphaco

Daewoong Pharmaceutical announced on March 14 that it is negotiating with Vietnam’s second-biggest drug maker Traphaco to expand its presence in the country. The South Korean firm acquired a 15 percent stake in the Vietnamese firm as a strategic investor last year and has a memorandum of underst...
March 14, 2019
SillaJen delays schedule for additional fundraising

SillaJen has delayed its board meeting, which was expected to confirm its decision for securing new funds worth around 220 billion won ($194.89 million), according to industry sources on March 14. The board was originally set to meet on March 12 to deliberate on its plans for securing fresh funds...
March 13, 2019
SillaJen stock price fluctuates on Pexa-Vec news

South Korea’s biotherapeutics company SillaJen ’s stock price fluctuated after a local news outlet reported that the future of its drug candidate Pexa-Vec was murky. Pexa-Vec, which is undergoing phase 3 clinical trials, is an oncolytic virus with demonstrated intravenous delivery to tumors, i...
March 13, 2019
GemVax & KAEL recruits patients for Alzheimer’s therapy clinical trials

South Korean new drug developer GemVax & KAEL announced on March 13 that it has recruited 90 patients to conduct phase 2 clinical trials of its treatment for Alzheimer’s disease. “Since the trials required patients with severe Alzheimer’s disease who must be accompanied by a guardian, recruit...

1 2 3 4 5 6 7 8 9 10

EDITOR'S PICKS

Herald Corporation |
CEO : Jeon Chang-hyeop |
Huam-ro 4-gil 10, Yongsan-gu, Seoul, Korea |
Title : The Investor |
Date of registration : 2016.06.21 |
Date of issue : 2016.06.21

Publisher. Editor : Jeon Chang-hyeop |
Chief Privacy Officer & Juvenile Protection Manager : Ahn Sung-mi |
T +82-2-727-0114

FAMILY SITE GO

Company Registration No. 104-81-06004 |
Mail-Order Business Registration 2016 - Seoul Yongsan - 00590 |
Business info |
Gov’t registration No. Seoul 아04099